Accelerate your antibacterial drug discovery with Cytoskeleton’s FtsZ-based assay services. FtsZ is a key target for next-gen antibiotics, and our validated, ready-to-run assays deliver fast turnaround and reliable results, driving your pipeline from concept to candidate with confidence.
FtsZ, a prokaryotic tubulin homolog key to bacterial cell division, is an attractive target for next-gen antibiotics. Cyto offers an ELIPA-based kinetic GTPase assay and an absorbance-based polymerization assay to monitor FtsZ activity, along with FtsZ proteins from a wide range of pathogens to assess compound specificity. With deep expertise in FtsZ biochemistry, we can also purify FtsZ from any bacterial species to support your custom research needs.
Parameter | Cyto services | Uniprot ID | Datasheet | Inquire |
|---|---|---|---|---|
FtsZ source | E. coli | |||
S. aureus | ||||
S. pneumoniae | ||||
E. faecalis | ||||
Other | na | |||
Assays | GTPase activity | na | ||
Polymerization assay | na |
Cytoskeleton partners closely with your team to deliver FtsZ-based assays, leveraging deep expertise in FtsZ biochemistry. Our high-quality data supports key project decisions, while our focus on collaboration and reliability keeps leading pharma and biotech companies returning year after year.
Our client submitted a focused library of small-molecule compounds for screening against the Staphylococcus aureus FtsZ protein, with the objective of identifying potential inhibitors to support antimicrobial drug development efforts.
Cytoskeleton, Inc. optimized two complementary assay formats to evaluate modulation of FtsZ activity. The first assay measured polymerization via light scattering, which reflects the formation of higher-order filamentous structures. The second assay was a GTPase activity assay, which quantified the intrinsic enzymatic function of FtsZ. Following an initial screen of the parent compound library, successive rounds of structure–activity relationship (SAR) optimization were conducted, ultimately yielding sub-micromolar inhibitors with improved potency.
We proudly support leading research teams across pharma, biotech, and academia. Our custom services have helped advance discovery and preclinical programs in oncology, neuroscience, cardiology, and beyond.
© 2026 Cytoskeleton, Inc All Rights Reserved.